<?xml version='1.0' encoding='utf-8'?>
<document id="25571293"><sentence text="Pharmacokinetic modeling of simvastatin, nelfinavir and their interaction in humans."><entity charOffset="28-39" id="DDI-PubMed.25571293.s1.e0" text="simvastatin" /><entity charOffset="41-51" id="DDI-PubMed.25571293.s1.e1" text="nelfinavir" /><pair ddi="false" e1="DDI-PubMed.25571293.s1.e0" e2="DDI-PubMed.25571293.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s1.e0" e2="DDI-PubMed.25571293.s1.e1" /></sentence><sentence text="Simvastatin, a commonly used HMG-CoA reductase inhibitor, is extensively metabolized by CYP3A4"><entity charOffset="0-11" id="DDI-PubMed.25571293.s2.e0" text="Simvastatin" /></sentence><sentence text=" Therefore, co-administration of simvastatin and CYP3A4 inhibitor can affect simvastatin pharmacokinetics"><entity charOffset="33-44" id="DDI-PubMed.25571293.s3.e0" text="simvastatin" /><entity charOffset="77-88" id="DDI-PubMed.25571293.s3.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25571293.s3.e0" e2="DDI-PubMed.25571293.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s3.e0" e2="DDI-PubMed.25571293.s3.e1" /></sentence><sentence text=" Nelfinavir, a protease inhibitor, and its major metabolite (M8) are known to be potent CYP3A4 inhibitors"><entity charOffset="1-11" id="DDI-PubMed.25571293.s4.e0" text="Nelfinavir" /></sentence><sentence text=" When simvastatin and nelfinavir are co-administered, simvastatin pharmacokinetics is significantly altered and may result in an increased risk of rhabdomyolysis"><entity charOffset="6-17" id="DDI-PubMed.25571293.s5.e0" text="simvastatin" /><entity charOffset="22-32" id="DDI-PubMed.25571293.s5.e1" text="nelfinavir" /><entity charOffset="54-65" id="DDI-PubMed.25571293.s5.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25571293.s5.e0" e2="DDI-PubMed.25571293.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s5.e0" e2="DDI-PubMed.25571293.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25571293.s5.e0" e2="DDI-PubMed.25571293.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25571293.s5.e1" e2="DDI-PubMed.25571293.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25571293.s5.e1" e2="DDI-PubMed.25571293.s5.e2" /></sentence><sentence text="" /><sentence text="To develop a mathematical model describing a drug-drug interaction between simvastatin and nelfinavir in humans"><entity charOffset="75-86" id="DDI-PubMed.25571293.s7.e0" text="simvastatin" /><entity charOffset="91-101" id="DDI-PubMed.25571293.s7.e1" text="nelfinavir" /><pair ddi="false" e1="DDI-PubMed.25571293.s7.e0" e2="DDI-PubMed.25571293.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s7.e0" e2="DDI-PubMed.25571293.s7.e1" /></sentence><sentence text="" /><sentence text="Eligible pharmacokinetic studies were selected from Pubmed database and concentration time course data were digitally extracted and used for model development" /><sentence text=" Compartmental pharmacokinetic models for simvastatin and nelfinavir were developed separately"><entity charOffset="42-53" id="DDI-PubMed.25571293.s10.e0" text="simvastatin" /><entity charOffset="58-68" id="DDI-PubMed.25571293.s10.e1" text="nelfinavir" /><pair ddi="false" e1="DDI-PubMed.25571293.s10.e0" e2="DDI-PubMed.25571293.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s10.e0" e2="DDI-PubMed.25571293.s10.e1" /></sentence><sentence text=" A drug-drug interaction model of simvastatin and nelfinavir was subsequently developed using the prior information"><entity charOffset="34-45" id="DDI-PubMed.25571293.s11.e0" text="simvastatin" /><entity charOffset="50-60" id="DDI-PubMed.25571293.s11.e1" text="nelfinavir" /><pair ddi="false" e1="DDI-PubMed.25571293.s11.e0" e2="DDI-PubMed.25571293.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s11.e0" e2="DDI-PubMed.25571293.s11.e1" /></sentence><sentence text=" Finally, the final drug-drug interaction modeled was validated against observed simvastatin concentrations"><entity charOffset="81-92" id="DDI-PubMed.25571293.s12.e0" text="simvastatin" /></sentence><sentence text="" /><sentence text="Three compartmental pharmacokinetic models were successfully developed" /><sentence text=" Simvastatin pharmacokinetics was best described by a one compartment model for simvastatin linked to its active form, simvastatin hydroxy acid"><entity charOffset="1-12" id="DDI-PubMed.25571293.s15.e0" text="Simvastatin" /><entity charOffset="80-91" id="DDI-PubMed.25571293.s15.e1" text="simvastatin" /><entity charOffset="119-143" id="DDI-PubMed.25571293.s15.e2" text="simvastatin hydroxy acid" /><pair ddi="false" e1="DDI-PubMed.25571293.s15.e0" e2="DDI-PubMed.25571293.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s15.e0" e2="DDI-PubMed.25571293.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25571293.s15.e0" e2="DDI-PubMed.25571293.s15.e2" /><pair ddi="false" e1="DDI-PubMed.25571293.s15.e1" e2="DDI-PubMed.25571293.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25571293.s15.e1" e2="DDI-PubMed.25571293.s15.e2" /></sentence><sentence text=" Nelfinavir pharmacokinetics could be adequately described by a one compartment parent-metabolite model"><entity charOffset="1-11" id="DDI-PubMed.25571293.s16.e0" text="Nelfinavir" /></sentence><sentence text=" Our final drug-drug interaction model predicted an increase in simvastatin exposure which is in line with clinical observations linking the simvastatin-nelfinavir combination to an increased risk of rhabdomyolysis"><entity charOffset="64-75" id="DDI-PubMed.25571293.s17.e0" text="simvastatin" /><entity charOffset="141-152" id="DDI-PubMed.25571293.s17.e1" text="simvastatin" /><entity charOffset="153-163" id="DDI-PubMed.25571293.s17.e2" text="nelfinavir" /><pair ddi="false" e1="DDI-PubMed.25571293.s17.e0" e2="DDI-PubMed.25571293.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s17.e0" e2="DDI-PubMed.25571293.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25571293.s17.e0" e2="DDI-PubMed.25571293.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25571293.s17.e1" e2="DDI-PubMed.25571293.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25571293.s17.e1" e2="DDI-PubMed.25571293.s17.e2" /></sentence><sentence text="" /><sentence text="Simvastatin-nelfinavir pharmacokinetic interaction can be explained by our final model"><entity charOffset="0-11" id="DDI-PubMed.25571293.s19.e0" text="Simvastatin" /><entity charOffset="12-22" id="DDI-PubMed.25571293.s19.e1" text="nelfinavir" /><pair ddi="false" e1="DDI-PubMed.25571293.s19.e0" e2="DDI-PubMed.25571293.s19.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s19.e0" e2="DDI-PubMed.25571293.s19.e1" /></sentence><sentence text=" This model framework will be useful in further advanced developing other mechanism based drug-drug interaction model used to predict the risk of rhabdomyolysis occurrence in patients prescribed simvastatin and nelfinavir concurrently"><entity charOffset="195-206" id="DDI-PubMed.25571293.s20.e0" text="simvastatin" /><entity charOffset="211-221" id="DDI-PubMed.25571293.s20.e1" text="nelfinavir" /><pair ddi="false" e1="DDI-PubMed.25571293.s20.e0" e2="DDI-PubMed.25571293.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25571293.s20.e0" e2="DDI-PubMed.25571293.s20.e1" /></sentence><sentence text="" /></document>